Dr. Craig Eagle currently serves as Guardant Health’s chief medical officer. Prior to joining
Guardant Health, Dr. Eagle served as Vice President of Medical Affairs Oncology for Genentech,
where he oversaw the medical programs across the oncology portfolio and developed innovative
cancer trials and strategies in personalized health care.

Prior to Genentech, Dr. Eagle has held several positions in the U.S. and internationally over his
19-year career at Pfizer including global head of the Oncology Medical and Outcomes Group. In
this role, he oversaw the worldwide medical programs and development of numerous
commercially successful drugs. Dr. Eagle currently serves on the Board of Directors for Generex
Biotechnology and NuGenerex Immuno-Oncology.

Dr. Eagle attended medical school at the University of New South Wales in Sydney, Australia
and received his general internist training at Royal North Shore Hospital in Sydney. Dr. Eagle
completed his specialist training in hemato-oncology and laboratory hematology at Royal Prince
Alfred Hospital in Sydney and was granted Fellowship in the Royal Australasian College of
Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA).